The Efficacy of switching from gonadotropin releasing hormone (GnRH) agonist to antagonist for the treatment of castration resistant prostate cancer (CRPC) patients.
Not Applicable
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000015265
- Lead Sponsor
- Department of Urology, Chiba University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. receive radiation therapy within twelve weeks before dosage of degarelix. 2. when the investigator thinks the patient is ineligible. 3. other systemic disease which is severe or uncontrollable. 4. severe allergy to degarelix.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PSA response.
- Secondary Outcome Measures
Name Time Method Total prostate volume, Serum testosterone, LH, FSH, BAP, IPSS, safety (CTCAE ver. 4.0), QO